Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis.
Affiliation
Rheumatology Rehabilitation, Our Lady's Hospice, Dublin, and School of Nursing and Midwifery, Trinity College, Dublin, Ireland. pminnock@olh.ieIssue Date
2010MeSH
AdolescentAdult
Aged
Antirheumatic Agents
Arthritis, Psoriatic
Fatigue
Female
Humans
Linear Models
Male
Middle Aged
Outcome Assessment (Health Care)
Pain
Pilot Projects
Sensitivity and Specificity
Treatment Outcome
Tumor Necrosis Factor-alpha
Young Adult
Metadata
Show full item recordCitation
Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis., 28 (3):401-4 Clin. Exp. Rheumatol.Journal
Clinical and experimental rheumatologyPubMed ID
20525443Abstract
This pilot study examined sensitivity to change and relative independence of fatigue as an outcome measure in patients with psoriatic arthritis (PsA) following anti-TNF therapy.Patients with PsA commencing anti-TNF therapy were evaluated at baseline and at 3 months. Fatigue was measured using a 0-10 numeric rating scale (NRS). This was a one-dimensional 11-point NRS with anchors of 0 (none) and 10 (a great deal). The words 'none' and 'a great deal' were placed under the NRS corresponding to the anchors 0 and 10, respectively. Sensitivity to change of fatigue was compared with recognised core outcomes and determined by calculating the standardised response means. Multiple regression analysis was employed to determine predictors of fatigue and their independent variance.
Forty-one patients were evaluated. Mean (SD) fatigue levels were 5.6 (2.3) and 3.6 (2.2) (p=0.001) at baseline and at 3-months, respectively. Using the SRM, fatigue ranked sixth relative to the other measures demonstrating a moderate sensitivity to change. Noteworthy was the observation that fatigue was ranked higher than CRP. The relative independent variance in fatigue of 27% was greater than that of the core clinical measures: HAQ 21%, TJC 14%, Pain 4%, SJC 0.4%, GH 0.4%, and less than that of the laboratory measure CRP 33%.
This study demonstrated that fatigue is an independent outcome measure and is sensitive to change in patients with PsA.
Item Type
ArticleLanguage
enISSN
0392-856XCollections
Related articles
- Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis.
- Authors: Minnock P, Kirwan J, Bresnihan B
- Issue date: 2009 Dec
- A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
- Authors: Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK, EULAR PsAID Taskforce
- Issue date: 2014 Jun
- Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
- Authors: Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M
- Issue date: 2011 Jul
- Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
- Authors: Perrotta FM, Marchesoni A, Lubrano E
- Issue date: 2016 Feb
- The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
- Authors: Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK
- Issue date: 2007 Aug